ProfileGDS5678 / 1435076_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 67% 71% 67% 67% 70% 67% 67% 56% 66% 72% 72% 69% 67% 67% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.1024567
GSM967853U87-EV human glioblastoma xenograft - Control 24.5009971
GSM967854U87-EV human glioblastoma xenograft - Control 34.1003367
GSM967855U87-EV human glioblastoma xenograft - Control 44.07267
GSM967856U87-EV human glioblastoma xenograft - Control 54.3221870
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.1098367
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.0951667
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.4263256
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.0153566
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.6379972
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.6032372
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.2723169
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.0954267
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.0945167